Butterfly Network (BFLY) Q3 2025: IQ3 Drives 85% Probe Volume, AI and Chip Roadmap Signal Multi-Year Leverage

October 31, 2025 | By EarningsIQ Research

Butterfly Network’s Q3 reveals a pivotal shift as IQ3’s rapid adoption now dominates probe mix and sets a new pricing benchmark, while AI-enabled solutions and next-gen chip launches are poised to expand the company’s addressable market and operational leverage. Despite macro-driven deal delays and a non-cash inventory write-down, Butterfly’s disciplined execution, expanding software ecosystem, and accelerating AI roadmap reinforce its long-term strategic positioning. Investors should watch for enterprise deal closures and the transition from device sales to integrated solution offerings as key catalysts into 2026.

Summary

  • IQ3 Adoption Redefines Product Mix: Rapid IQ3 uptake shifted probe volume and established a higher price point.
  • AI and Chip Platform Catalyze Leverage: New AI tools and P5.1 chip roadmap set up Butterfly for multi-year technology and margin expansion.
  • Enterprise Pipeline Stacks Up: Macro-driven deal delays stack opportunities for 2026, with Compass AI and solution sales in focus.

Business Overview

Butterfly Network develops and sells handheld, semiconductor-based point-of-care ultrasound (POCUS) devices and associated software. The company monetizes through hardware sales, software subscriptions, and services, with a growing emphasis on enterprise and AI-driven solutions. Its major segments include product (probes and hardware) and software/services (subscriptions, partnerships, and extended warranties), serving healthcare, veterinary, and educational markets globally.

Performance Analysis

Butterfly delivered Q3 revenue at the high end of guidance, with 5% growth year-over-year, driven by strong IQ3 probe adoption and higher average selling prices, particularly in international markets. Product revenue rose 8% as IQ3 accounted for 85% of probe volume, sharply outpacing legacy IQ Plus units. This mix shift prompted a $17.4 million non-cash write-down for excess IQ Plus inventory, reflecting the company’s rapid transition to its latest technology and a more favorable margin profile.

Software and services revenue was flat, as higher licensing and partnership income was offset by lower individual subscription renewals and extended warranty revenue, the latter due to longer standard warranties on IQ3. Adjusted gross margin improved to 63.9%, up from 60% last year, aided by price and lower amortization, while normalized cash burn declined to $3.9 million. The company closed the quarter with $148 million in cash, maintaining a disciplined approach to expense control.

  • Probe Mix Shift: IQ3’s rapid adoption drove 85% of probe volume, setting a new price and margin benchmark.
  • Inventory Write-Down: Non-cash charge reflects faster-than-expected IQ3 uptake and prudent inventory management.
  • Software Churn: Individual subscription renewals softened, but enterprise pipeline and new AI offerings position for future growth.

Deal delays in the US hospital and enterprise channels weighed on Q3, yet the pipeline remains active with several large opportunities poised to close as macro headwinds abate and new budget cycles begin in 2026.

Executive Commentary

"We were able to keep growing on top of that very strong quarter a year ago. We knew coming into 2025, we would have the anniversary of Big Year and new product launch. ... Our pipeline opportunities have increased. We believe we're starting to see the cloud lifting. I expect we'll return to the momentum we're used to in 2026 and may even see early signs in the current quarter."

Joseph DeVivo, Chairman and Chief Executive Officer

"In quarter three, for example, IQ3 accounted for approximately 85% of our probe volume and IQ Plus represented the remaining 15. While IQ Plus will continue to serve as the lower cost alternative and address targeted use cases, our earlier forecast assumed a greater share of demand from IQ Plus. We've since refined our forecast to reflect the actual product mix and market trajectory, resulting in the write down."

Megan Carlson, Interim Chief Financial Officer

Strategic Positioning

1. IQ3 Establishes New Baseline for Product and Margin Mix

IQ3’s dominance in probe volume (85%) signals a decisive technology shift, enabling Butterfly to command higher average selling prices and improved gross margins. The rapid transition validates the company’s product development cadence and supports a more profitable business model, as legacy IQ Plus is repositioned for targeted, lower-cost use cases.

2. AI Ecosystem and Software Flywheel

Butterfly’s AI-powered tools are translating into measurable clinical and economic value, as highlighted by the Rutgers/JAMA study showing a 30% reduction in hospital length of stay and over $750,000 in cost savings. The upcoming Compass AI launch and Butterfly Garden ecosystem expand the addressable market by lowering the training barrier and enabling new use cases, especially in enterprise and education.

3. Chip Roadmap: P5.1 and Apollo AI

The completion of the P5.1 chip and the initiation of Apollo AI development mark a step-change in Butterfly’s technology platform. P5.1 is expected to surpass piezo-based competitors, while Apollo AI’s on-device processing power will enable local AI inference, reducing latency and unlocking new clinical applications. This positions Butterfly as both a device and a semiconductor platform company, with potential to expand into broader medical imaging markets.

4. Enterprise and Solutions-Led Model

Leadership is pivoting from a hardware-only sales approach to integrated solutions, bundling devices with software, services, and hands-on support. This strategy aims to address the needs of large, risk-bearing providers and insurance partners, with several commercial agreements in late-stage negotiation. The shift is expected to drive higher recurring revenue and deeper customer integration.

5. Cloud Security and Regulatory Readiness

Butterfly’s leadership in cloud connectivity and security certifications (ISO 27001, with HITRUST and FedRAMP on the horizon) is a competitive differentiator as the industry shifts from on-premise to cloud-based imaging. This underpins enterprise sales and supports global expansion, especially as competitors scramble to catch up.

Key Considerations

Butterfly’s Q3 underscores a business at a critical inflection, balancing near-term macro headwinds with long-term technology and market leadership. The rapid IQ3 adoption, robust AI ecosystem, and disciplined cash management set the stage for operational leverage and strategic expansion.

Key Considerations:

  • Enterprise Deal Timing: Large US hospital and enterprise deals remain delayed but active, with budget cycles and macro stabilization likely to unlock closures in 2026.
  • Software Revenue Mix: Flat software/services revenue and individual subscription churn highlight the importance of new enterprise offerings and AI-driven upsell opportunities.
  • AI Validation and Clinical Impact: Published studies and new AI tools provide strong proof points to accelerate enterprise adoption and payer partnerships.
  • Chip Innovation as TAM Multiplier: The P5.1 and Apollo AI chips position Butterfly to expand beyond POCUS into the broader medical imaging and semiconductor markets.
  • Regulatory and Macro Sensitivity: Ongoing FDA review, potential government shutdown impacts, and European regulatory processes introduce timing risks but are not currently material headwinds.

Risks

Deal closure timing remains uncertain due to macroeconomic pressures and extended sales cycles in US hospital and enterprise markets. Regulatory delays, especially from a prolonged US federal shutdown or European ROS review, could impact product launches and revenue recognition. Individual software subscription churn and reliance on large deal closures for Q4 and 2026 growth add execution and forecasting risk. While Butterfly’s cash position is strong, sustained delays or competitive responses could pressure near-term results and valuation.

Forward Outlook

For Q4 2025, Butterfly guided to:

  • Revenue of $25 to $29 million (to achieve the upper end, large enterprise deals must close)
  • Adjusted EBITDA loss of $9 to $12 million

For full-year 2025, management reaffirmed guidance:

  • Revenue of $91 to $95 million
  • Adjusted EBITDA loss of $32 to $35 million

Management highlighted several factors that will shape results:

  • Enterprise deal closures remain the swing factor for Q4 and 2026 momentum
  • Compass AI launch and further AI ecosystem expansion offer upside for software and service revenue

Takeaways

  • IQ3’s rapid adoption and margin impact are structural, not cyclical, positioning Butterfly for improved financial leverage as legacy hardware recedes.
  • AI-driven solutions and the chip roadmap represent long-term TAM expansion, as Butterfly moves from device sales to a platform and solutions model with recurring revenue potential.
  • Investors should watch for large enterprise deal closures, Compass AI adoption, and further updates on the P5.1 and Apollo AI chips as key catalysts for 2026 and beyond.

Conclusion

Butterfly Network’s Q3 2025 shows a company executing through macro headwinds while laying the foundation for multi-year growth via technology, AI, and enterprise solutions. The rapid IQ3 mix shift, expanding AI ecosystem, and disciplined cost control provide tangible evidence of strategic progress, though deal timing and regulatory processes remain near-term watchpoints. The next phase hinges on solution sales, AI platform adoption, and chip-driven market expansion.

Industry Read-Through

Butterfly’s Q3 highlights the accelerating shift in medical imaging from hardware-centric to AI-enabled, cloud-connected platforms, with device-software integration and security certifications becoming key competitive differentiators. The company’s rapid product mix evolution and margin expansion underscore the disruptive potential of semiconductor innovation in healthcare. Competitors relying on legacy piezo technology or on-premise software risk losing share as hospitals and providers seek flexible, scalable, and AI-driven imaging solutions. Enterprise sales cycles remain elongated industry-wide, but published clinical and economic validation of AI tools will likely become table stakes for adoption. Investors should monitor how other imaging and medtech players respond to Butterfly’s chip and AI roadmap as the sector pivots toward integrated, platform-based value propositions.

BFLY Health Care Medical Devices AI Semiconductors POCUS Cloud Enterprise